{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:42:20Z","timestamp":1791229340545,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2002,1]]},"DOI":"10.1136\/ard.61.1.59","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:29:07Z","timestamp":1027765747000},"page":"59-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Intravenous immunoglobulins control scleromyxoedema"],"prefix":"10.1016","volume":"61","author":[{"given":"A","family":"Righi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Schiavon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Jablonska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Blasczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Rondinone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Todesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Matucci","family":"Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.61.1.59_bib1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0190-9622(98)70567-5","article-title":"Fatal scleromyxedema: report of a case and review of the literature","volume":"38","author":"Godby","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.61.1.59_bib2","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1365-4362.1989.tb02439.x","article-title":"Scleromyxedema associated with non-Hodgkin lymphoma","volume":"28","author":"Gimenez Garcia","year":"1989","journal-title":"Int J Dermatol"},{"key":"10.1136\/ard.61.1.59_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/00313029109063575","article-title":"Myeloma associated scleromyxedema with extensive involvement of small bowel","volume":"23","author":"Dowling","year":"1991","journal-title":"Pathology"},{"key":"10.1136\/ard.61.1.59_bib4","first-page":"960","article-title":"Arndt Gottron scleromyxedema. Summary of 2 years treatment","volume":"109","author":"Krajnc","year":"1997","journal-title":"Wien Klin Wochenschr"},{"key":"10.1136\/ard.61.1.59_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0190-9622(95)90007-1","article-title":"Scleromyxedema","volume":"33","author":"Dinneen","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.61.1.59_bib6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2133.1979.tb08080.x","article-title":"Spontaneous resolution of lichen myxoedematosus","volume":"100","author":"Hardie","year":"1979","journal-title":"Br J Dermatol"},{"issue":"suppl 15","key":"10.1136\/ard.61.1.59_bib7","first-page":"S17","article-title":"Immunomodulatory effect of immunoglobulins","volume":"14","author":"Wolf","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.61.1.59_bib8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1067\/mjd.2000.104001","article-title":"Scleromyxedema: response to high dose intravenous immunoglobulin (hdIVIg)","volume":"43","author":"Lister","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.61.1.59_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s100670050158","article-title":"Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin\u2014a preliminary report","volume":"19","author":"Levy","year":"2000","journal-title":"Clin Rheumatol"},{"issue":"suppl 15","key":"10.1136\/ard.61.1.59_bib10","first-page":"S85","article-title":"High dose intravenous immunoglobulin therapy for rheumatic disease: clinical relevance and personal experience","volume":"14","author":"De Vita","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.61.1.59_bib11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1081-1206(10)62785-8","article-title":"Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy","volume":"84","author":"Huang","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1136\/ard.61.1.59_bib12","first-page":"227","article-title":"Mechanism of intravenous immune globulin therapy in antibody mediated autoimmune diseases","volume":"340","author":"Zhiya","year":"1999","journal-title":"Clinical Implication of Basic Research"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724095013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724095013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.61.1.59","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T09:00:54Z","timestamp":1736067654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724095013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["S0003496724095013"],"URL":"https:\/\/doi.org\/10.1136\/ard.61.1.59","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2002,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous immunoglobulins control scleromyxoedema","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.61.1.59","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Copyright 2002 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}